Financials in USD. Standardized financial statements.
A compact view of how Kronos Bio, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue? | $9.85M | $6.29M | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +56.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $4.46M | $4.08M | $4.87M | $605,000 | $160,000 |
| Gross Profit? | $9.85M | $6.29M | -$4.46M | -$4.08M | -$4.87M | -$605,000 | -$160,000 |
| Gross Margin? | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $102.73M | $128.12M | $137.12M | $151.40M | $58.04M | $16.82M | $6.64M |
| Operating Income? | -$92.89M | -$121.83M | -$137.12M | -$151.40M | -$58.04M | -$16.82M | -$6.64M |
| EBITDA? | -$61.72M | -$119.69M | -$128.74M | -$147.00M | -$79.69M | -$15.51M | -$6.49M |
| Income Before Tax | -$86.08M | -$112.67M | -$133.20M | -$151.08M | -$88.44M | -$16.12M | -$6.72M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$86.08M | -$112.67M | -$129.29M | -$149.10M | -$64.09M | -$15.42M | -$6.72M |
| EPS? | $-1.43 | $-1.95 | $-2.30 | $-2.72 | $-1.19 | $-0.29 | $-0.24 |
| Diluted EPS? | $-1.43 | $-1.95 | $-2.30 | $-2.72 | $-1.19 | $-0.29 | $-0.24 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality